Checkmate 9la trial#
Checkmate 9la tv#

Turning Point Therapeutics and The University of Texas MD Anderson Cancer Center announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.

Checkmate 9la tv#

This trend remained stable or improved over 4-5 years of Zeposia treatment, leading to improved or preserved cognitive function in almost 80% of people with high TV and approximately 66% of people with low BV at Month 48 of the Phase 3 DAYBREAK OLE study. Findings from the new research showed that people with high versus low BV, particularly TV, had higher cognitive performance, as assessed by the symbol digit modalities test score, at baseline.

Checkmate 9la trial#

Zeposia was well tolerated with more than 80% of people who started the Phase 3 SUNBEAM trial remaining on continuous therapy through 48 months of the Phase 3 DAYBREAK OLE study. In these new exploratory analyses, Zeposia treatment showed improved or preserved cognitive function in a majority of patients, with the greatest improvement seen when used early in the disease when TV remains high, supporting a positive association between preserved BV and long-term cognitive performance.

These data are being presented at the European Academy of Neurology Congress taking place in Vienna, Austria, from June 25-28. This observation may be helpful for physicians as they seek to optimize care for patients in the face of the ongoing COVID-19 pandemic,' said Bruce Cree, MD, PhD, MAS, study investigator and professor of Clinical Neurology, University of California San Francisco Weill Institute for Neurosciences and clinical research director, UCSF MS Center.īristol Myers Squibb announced new post-hoc analyses from the Zeposia Phase 3 DAYBREAK open-label extension and Phase 3 SUNBEAM trials, showing early Zeposia use demonstrated cognitive benefits in people with relapsing multiple sclerosis, with the greatest effect seen in people with high thalamic volume, supporting an association between preserved brain volume and improved long-term cognitive outcomes. Patients treated with Zeposia are much more likely to develop antibody responses to RNA vaccines compared to non-RNA vaccines. 'This study shows that all participants who received Zeposia as a treatment for multiple sclerosis were able to develop an immune response following mRNA vaccinations against COVID-19 infection. In a separate analysis of treatment-emergent COVID-19 events occurring from Novemto May 10, 2021, results showed that the benefit:risk profile of Zeposia remains unchanged with most COVID-19 cases being non-serious, with the majority resolving without treatment interruption. This research was conducted from January 2020 to October 2021, and higher antibody levels were observed at all tested timepoints from four weeks to greater than 12 weeks in mRNA vaccine recipients who completed the two-dose regimen versus those with one dose, indicating that patients on Zeposia develop an adequate primary response and may receive a potential benefit from booster doses. These data are to be presented as late-breaking research on June 28, at the European Academy of Neurology, or EAN, Congress in Vienna, Austria.

For participants who showed no evidence of recent COVID-19 infection, results showed seroconversion occurred in 100% and 62% of fully vaccinated mRNA and non-mRNA vaccine recipients, respectively.

Bristol Myers Squibb announced new data on COVID-19 vaccine responses in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension, or OLE, study in relapsing multiple sclerosis.